A few years ago, Omar Rahman, MD, rarely heard the word “peptide” in an orthopedic exam room.
Now patients arrive asking about BPC-157, TB-500 and growth-hormone-related compounds after hearing about them from friends, podcasts, Reddit threads or social media. They know the acronyms. They have read the testimonials. Some want to know where peptides fit between physical therapy and surgery. Others arrive ready to ask for a prescription.
The demand has moved faster than the evidence.
That places orthopedic physicians in an uncomfortable position. The compounds are no longer obscure enough to ignore, yet most are not supported by the kind of rigorous human data that would make them routine treatments for tendon injuries, ligament damage or early arthritis.
Dr. Rahman, an orthopedic surgeon and sports medicine specialist at DISC Marina Del Rey (Calif.), believes the discussion has been distorted from both directions. Peptides are sometimes marketed as regenerative shortcuts capable of repairing almost anything. They are also dismissed broadly as unsafe or illegitimate because many lack FDA approval for orthopedic use. Neither position, he argues, is precise enough.
“When someone asks, ‘What do you think about peptides?’ that’s like asking, ‘What do you think about medications?'” Dr. Rahman told Becker’s. “You have to get more specific.”
His answer is not an endorsement of the peptide market as it exists today. It is a case for orthopedics to take control of a conversation that patients are already having, by defining the compounds, explaining what is known, collecting what is missing and refusing to let marketing outrun medicine.
One word, radically different treatments
“Peptides” has become a catchall term for a wide range of compounds that behave very differently inside the body. GLP-1 receptor agonists, including medications used for diabetes and obesity, are peptide-based drugs. So are many of the compounds being promoted online for muscle growth, tendon healing, fat loss and recovery. Sharing a chemical category does not mean they share a mechanism, evidence base or regulatory status.
That is the first distinction Dr. Rahman tries to establish with patients. The second is that “natural” does not necessarily mean safe.
Many peptides resemble signaling molecules produced by the body, which can make them seem inherently less risky than conventional medications. But a compound manufactured in a laboratory is still a manufactured medical product. Its quality depends on whether the formulation contains the correct dose, remains sterile and has been tested for potency, contaminants and endotoxins.
Insulin is naturally produced by the body, Dr. Rahman noted. A patient receiving insulin still needs a pharmaceutical product manufactured and monitored to a reliable standard.
“Just because it is a naturally occurring sequence does not mean it is automatically safe,” he said.
The reverse misconception can be equally misleading. Lack of FDA approval does not, by itself, prove a compound is dangerous. It does mean the agency has not determined that the product is safe and effective for that intended use.
Dr. Rahman points to platelet-rich plasma and bone marrow aspirate concentrate as examples of therapies already used in orthopedic care despite regulatory and evidence questions that remain unsettled. The devices used to prepare those products may have FDA clearance, while many of the ways clinicians inject the resulting biologics are not specifically FDA-approved.
The lesson, he said, is not that unapproved treatments should be accepted casually. It is that regulatory status, biological plausibility and clinical evidence are separate questions, and patients deserve an honest explanation of all three.
The science is promising. The human evidence is not there yet.
The peptides generating the most orthopedic interest are intended to influence parts of the body’s healing response.
After an injury, tissue generally moves through phases of inflammation, cellular proliferation and remodeling. Peptide advocates argue that certain compounds can influence pathways involved in blood-vessel formation, collagen production, cell migration or muscle recovery.
Among the most discussed is BPC-157. Dr. Rahman said the compound has a substantial body of preclinical research, including animal studies examining tendon, muscle, gastrointestinal tissue and blood-flow signaling. But animal evidence is not human evidence.
“We cannot automatically make the jump that because it worked in rodents or mice, it will have the exact same effect in humans,” he said.
The published human literature remains limited. Dr. Rahman pointed to a small case series involving injections into the knee and a separate small safety study of intravenous BPC-157. He described the findings as insufficient to draw strong conclusions about either efficacy or long-term safety.
Another commonly discussed compound, TB-500, is frequently paired with BPC-157. TB-500 is a synthetic fragment of thymosin beta-4, corresponding to that molecule’s actin-binding domain. Dr. Rahman cautioned that online discussions often blur the distinction between the two, and that full-length thymosin beta-4 has a longer and distinct research history.
GHK-Cu, a copper-containing peptide, has a more established presence in skin and wound research. Orthopedic interest centers on whether its role in collagen biology could eventually support scar remodeling or tissue repair.
The mechanisms may be biologically interesting. That does not establish a treatment. Dr. Rahman believes the most responsible clinicians must be comfortable holding both ideas at once: The science may justify further investigation, and the current evidence does not justify certainty.
The patients living in orthopedics’ gray zone
Dr. Rahman does not view peptides as replacements for standard orthopedic care. His treatment sequence remains familiar: activity modification, appropriate medication, physical therapy and surgery when conservative treatment fails and the indication is clear.
“I never let this change my standard of care,” he said.
The peptide question tends to arise in the space between those options. A patient may have persistent tendon pain despite rehabilitation but may not need surgery. Another may have an early meniscus or cartilage problem and want to avoid an invasive biologic procedure. Some do not want another corticosteroid injection because the relief is temporary or because repeated exposure can adversely affect tissue.
Cortisone remains an effective treatment for acute inflammation and pain, Dr. Rahman said, but it is not regenerative. Repeated or excessive use can damage tendon, cartilage or other structures.
Peptides appeal to patients because they are promoted as more targeted tools, compounds that may support the body’s healing response rather than simply suppress inflammation.
The key word, Dr. Rahman said, is support. A patient cannot inject a compound, ignore rehabilitation and expect a damaged tendon or joint to rebuild itself.
“It is not doing everything while you sit back and do nothing,” he said. For selected patients who understand the uncertainty, Dr. Rahman believes peptides may be considered within that gray zone. The conversation, however, must include what is missing as clearly as what is promising.
“We don’t know what we don’t know,” he said.
Turning anecdotes into evidence
Patients and clinicians are already using peptides, whether academic orthopedics is ready or not. Dr. Rahman believes the field’s responsibility is to begin measuring what happens.
He serves on the steering committee of the Orthopedic Peptide Evaluation Network, or OPEN, a registry intended to collect prospective information on peptide use. Edwin Spencer, MD, and Reza Jazayeri, MD, are co-principal investigators, and DataBiologics is the registry data partner.
The first objective is safety. The registry would track the compound used, dose, indication, laboratory monitoring and reported adverse events. Once a more reliable safety picture develops, researchers could examine pain, function, physical therapy progress and validated patient-reported outcomes.
For knee conditions, that might include Knee injury and Osteoarthritis Outcome Scores. Shoulder patients could be followed with American Shoulder and Elbow Surgeons scores. Athletes could be measured by their time to return to sport. The database could also help identify which types of patients respond, or do not respond, to a given compound.
A peptide might show little value across a broad orthopedic population but appear more promising in a narrower injury pattern. Another may produce enough adverse events that further use becomes difficult to justify.
Without organized data, neither conclusion is possible. Dr. Rahman has begun tracking patients within his own practice, including pain and functional milestones before and after peptide use. He said some patients with conditions such as tennis elbow or meniscus injuries have reported faster pain improvement or progress in physical therapy.
He is careful about what those observations mean. The findings are preliminary, unpublished and not part of a randomized clinical trial. They cannot show that peptides caused the improvement.
The value is in generating better questions. Can patients receiving a peptide reach rehabilitation milestones faster than comparable patients receiving standard care alone? Which doses are associated with improvement? Which injuries show no meaningful difference?
Those are testable questions. Testimonials are not.
The market has moved ahead of the guardrails
The evidence problem is inseparable from the product problem. Patients can find peptides through online vendors, fitness communities and other sources outside conventional medical care. The label may say BPC-157. The vial may not contain the stated concentration, or it may carry contamination that has nothing to do with the peptide itself.
Dr. Rahman believes any clinical use should involve a licensed practitioner and an appropriate pharmacy rather than an unverified internet or gym source. The product should be evaluated for sterility, purity, potency and endotoxins, he said.
“You would not get opioids on the street after a knee replacement,” he said. “You would get them from a pharmacy.”
Peptides should not be treated differently simply because the market has placed them in a wellness category.
The same principle applies to monitoring. A physician considering a compound intended to influence blood-vessel signaling or growth-related pathways must understand the patient’s medical history, concurrent medications and potential risks. The patient may require laboratory evaluation and follow-up.
That kind of oversight is difficult to provide during a brief surgical consultation. Dr. Rahman operates a separate regenerative and orthopedic longevity practice, Chronos Clinic, partly to create room for those discussions. The model combines conventional orthopedic evaluation with nutrition, sleep, exercise, physical therapy, orthobiologics and nonoperative modalities. Peptides are not intended to become the center of that model. They come after the foundation.
Health span before hype
Dr. Rahman is skeptical of the way the word “longevity” is often used in medicine. Living longer is not the same as living well.
“We’re trying to add not just years to our lives, but life to our years,” he said. For orthopedics, that means helping patients preserve mobility, strength and independence long before a catastrophic injury or end-stage arthritis forces an operation.
The field has traditionally been organized around episodes. The patient tears an ACL, develops severe shoulder pain or loses enough cartilage to require joint replacement. Orthopedics enters after the damage has occurred.
Dr. Rahman believes a health-span model starts earlier. Sleep, nutrition, exercise, metabolic health and strength are the first interventions. Those factors determine how well a patient heals, tolerates rehabilitation and maintains musculoskeletal function over time.
“You have to fix the brick and mortar before you start adding precision tools like peptides,” he said. Only after those fundamentals are addressed does it make sense to discuss whether a biologic treatment could further optimize recovery.
That hierarchy is important because peptides are often marketed in reverse. The precision intervention is sold first, while the daily behaviors that drive health receive less attention because they are slower, less novel and harder to package.
The future Dr. Rahman envisions is not one in which patients inject themselves indefinitely to avoid aging. It is one in which clinicians use carefully studied tools to support a broader plan for maintaining function.
Orthopedics has seen this story before
Dr. Rahman compares the current peptide moment with the early years of platelet-rich plasma. PRP arrived with biological plausibility, strong enthusiasm and highly variable products. Some clinics marketed it aggressively before researchers had standardized preparation methods, dose or indications.
The result was years of conflicting studies and confusion over whether researchers were even evaluating the same treatment.
Much of that work is still being resolved. Peptides risk following the same path.
“Marketing gets ahead of the science,” Dr. Rahman said.
Orthopedics can repeat that cycle, allowing influencers, sellers and enthusiastic early adopters to define the field before the evidence matures. Or it can apply the lesson. Specify the compound. Standardize the product. Establish safety. Track dosing. Collect outcomes. Separate biological theory from clinical benefit. Tell patients what the treatment might do without disguising what medicine still does not know.
The peptide question is no longer hypothetical. It is already sitting in orthopedic exam rooms. Whether these compounds ultimately become useful tools, narrow treatments for specific conditions or another overpromised chapter in regenerative medicine will depend on the evidence still to be built.
Dr. Rahman does not believe physicians should promise an answer before the science provides one. He also does not believe they can afford to leave the question to Reddit.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.